[1]张自萍.不同剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症的疗效分析[J].医学信息,2019,(07):155-157.[doi:10.3969/j.issn.1006-1959.2019.07.048]
 ZHANG Zi-ping.Therapeutic Effect of Different Doses of Venlafaxine and Agomelatinein the Treatment of Refractory Depression[J].Medical Information,2019,(07):155-157.[doi:10.3969/j.issn.1006-1959.2019.07.048]
点击复制

不同剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症的疗效分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年07期
页码:
155-157
栏目:
药物与临床
出版日期:
2019-04-01

文章信息/Info

Title:
Therapeutic Effect of Different Doses of Venlafaxine and Agomelatinein the Treatment of Refractory Depression
文章编号:
1006-1959(2019)07-0155-03
作者:
张自萍
(天津市安宁医院医务科,天津 300300)
Author(s):
ZHANG Zi-ping
(Department of Medical Affairs,Tianjin Anning Hospital,Tianjin 300300,China)
关键词:
文拉法辛阿戈美拉汀难治性抑郁症
Keywords:
different doses venlafaxine agomelatine treatment refractory depression
分类号:
R749.4
DOI:
10.3969/j.issn.1006-1959.2019.07.048
文献标志码:
A
摘要:
目的 研究不同剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症的疗效。方法 选取2017年6月~2018年8月我院收治的难治性抑郁症患者236例,随机分为观察组和对照组,每组118例。观察组采用大剂量文拉法辛与阿戈美拉汀治疗,对照组采用小剂量文拉法辛与阿戈美拉汀治疗,6周为1疗程,共治疗1个疗程。分析两组不同时间段(治疗2周、4周、6周末)HAMD-17评分和不良反应。结果 观察组治疗后2、4、6周HAMD-17评分分别为(17.21±1.02)分、(14.22±1.34)分、(10.03±1.21)分,均低于对照组的(21.64±1.57)分、(16.98±1.76)分、(13.88±1.97)分,差异具有统计学意义(P<0.05)。观察组不良反应发生率为1.69%,与对照组的2.54%比较,差异无统计学意义(P>0.05)。结论 使用大剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症,疗效显著,不仅能够改善患者抑郁症状,且具有极高安全性。
Abstract:
Objective To study the efficacy of different doses of venlafaxine and agomelatine in the treatment of refractory depression. Methods A total of 236 patients with refractory depression admitted to our hospital from June 2017 to August 2018 were randomly divided into observation group and control group, with 118 cases in each group. The observation group was treated with high-dose venlafaxine and agomelatine. The control group was treated with low-dose venlafaxine and agomelatine, and 6 weeks was a course of treatment for a total of 1 course of treatment. The HAMD-17 score and adverse reactions were analyzed at different time periods (2 weeks, 4 weeks, 6 weeks of treatment). Results The HAMD-17 scores of the observation group at 2, 4, and 6 weeks after treatment were (17.21±1.02), (14.22±1.34), and (10.03±1.21), respectively, which were lower than those of the control group (21.64±1.57). (16.98±1.76) and (13.88±1.97) points, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 1.69%, compared with 2.54% in the control group, the difference was not statistically significant (P>0.05). Conclusion The use of high-dose venlafaxine and agomelatine in the treatment of refractory depression has a significant effect, which not only improves the patient's depressive symptoms, but also has a high safety.

参考文献/References:


[1]况雷雨,谷传正,吉峰.阿戈美拉汀与5-HT再摄取抑制剂治疗抑郁症安全性的meta分析[J].中华行为医学与脑科学杂志,2016,25(6):565-571.
[2]叶庆红,陈志斌,唐锴,等.阿戈美拉汀联合高频经颅磁刺激治疗产后抑郁症疗效观察[J].临床精神医学杂志,2017,27(1):55.
[3]宁征远,谢姗姗,李健,等.阿戈美拉汀联合坦度螺酮对老年抑郁症患者血清NE、5-HT水平的影响[J].东南国防医药,2017,19(3):251-253.
[4]田丽,杨媛,胡永梅.阿戈美拉汀治疗重度抑郁症的临床疗效[J].神经疾病与精神卫生,2014,14(3):277-279.
[5]赵明军,毛亚阁,张瑞岭.低剂量阿立哌唑增效治疗难治性抑郁症的有效性和安全性的Meta分析[J].临床药物治疗杂志,2017,15(2):43-48.
[6]张琦,郭银淼,王慧娟,等.无抽搐电休克治疗难治性抑郁症疗效及对患者自杀意念改善情况观察[J].山东医药,2017,57(43):42-44.
[7]黄兴兵,黄雄,何红波,等.不同麻醉剂电休克治疗对难治性抑郁症患者认知功能的影响[J].广东医学,2017,38(1):119-122.

更新日期/Last Update: 2019-04-01